Elacentra 345 Mg (Elacestrant)

Description

Elacentra 345 Mg is an oral anticancer medicine containing the active ingredient Elacestrant. It is primarily used for the treatment of certain types of advanced or metastatic breast cancer in adults. This targeted therapy offers a new treatment option for patients whose cancer has progressed after previous hormone-based therapies. By specifically acting on estrogen receptors, Elacentra helps slow tumor growth and may improve disease control in eligible patients.

Breast cancer remains one of the most commonly diagnosed cancers worldwide, and hormone receptor-positive cancers account for a large percentage of cases. Elacentra 345 Mg was developed to address resistance that can develop with traditional endocrine therapies, providing an effective alternative for patients with specific genetic alterations.

How Elacentra 345 Mg Works

Elacestrant belongs to a class of medicines known as selective estrogen receptor degraders (SERDs). Estrogen can stimulate the growth of hormone receptor-positive breast cancer cells. Elacestrant binds to estrogen receptors and promotes their degradation, reducing the ability of cancer cells to receive growth signals.

Unlike some older endocrine therapies that only block estrogen activity, Elacestrant actively destroys estrogen receptors. This mechanism may be particularly beneficial in patients whose tumors harbor mutations in the ESR1 gene, which can contribute to resistance against conventional hormonal treatments.

Benefits of Estrogen Receptor Degradation

By eliminating estrogen receptors from cancer cells, Elacentra 345 Mg may:

Slow the progression of breast cancer
Delay the need for chemotherapy
Provide an oral treatment option that can be taken at home
Offer effectiveness in patients with ESR1-mutated tumors
Improve disease management after prior endocrine therapies fail
Uses of Elacentra 345 Mg

Elacentra 345 Mg is indicated for adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, particularly in cases where the disease has worsened following endocrine therapy.

Conditions Treated

Patients may be considered for Elacentra treatment if they have:

Estrogen receptor-positive breast cancer
HER2-negative disease
Advanced or metastatic cancer
Tumors carrying ESR1 mutations
Disease progression after previous hormonal therapies

Healthcare providers may perform genetic testing to determine whether a patient is likely to benefit from Elacestrant therapy.

Dosage and Administration

Recommended Dose

The usual recommended dose of Elacentra is 345 mg taken orally once daily. The tablet should be swallowed whole with water and preferably taken at the same time each day.

Important Administration Tips
Take the medicine with food to enhance absorption.
Do not crush, split, or chew the tablets.
If a dose is missed, follow your doctor’s instructions regarding when to take the next dose.
Continue treatment until disease progression or unacceptable side effects occur.

Patients should always adhere to the treatment plan prescribed by their healthcare professional.

Possible Side Effects

Like most anticancer medicines, Elacentra 345 Mg may cause side effects, although not everyone experiences them.

Common Side Effects

Some frequently reported side effects include:

Nausea
Fatigue
Decreased appetite
Vomiting
Joint pain
Constipation
Increased cholesterol levels
Diarrhea

Serious Side Effects

Seek immediate medical attention if any severe symptoms develop, such as:

Persistent vomiting
Severe weakness
Signs of liver problems
Difficulty breathing
Unusual swelling

Regular monitoring through blood tests may be recommended during treatment.

Precautions and Warnings

Before Starting Treatment

Patients should inform their healthcare provider about:

Existing liver disease
Current medications and supplements
Pregnancy or plans to become pregnant
Breastfeeding status
Previous cancer treatments
Pregnancy Considerations

Elacentra 345 Mg may harm an unborn baby. Women of childbearing potential should use effective contraception during treatment and for the period recommended by their physician after the final dose.

Breastfeeding

Breastfeeding is generally not recommended while taking Elacestrant because it is unknown whether the drug passes into breast milk.

Storage Instructions

Store Elacentra 345 Mg tablets at room temperature in their original packaging. Keep the medicine away from excessive heat, moisture, and direct sunlight. Always keep it out of the reach of children.

Conclusion

Elacentra 345 Mg (Elacestrant) represents an important advancement in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer. Its ability to degrade estrogen receptors provides a targeted approach for patients who have developed resistance to earlier endocrine therapies. When used under medical supervision, Elacentra may help improve disease control and offer a convenient oral treatment option for suitable patients.